Bringing the Oncology Community Together

Dr. Rotkowitz on the Dabrafenib/Trametinib Combination

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on the Dabrafenib Plus Trametinib Combination for Melanoma

Conferences   >   2012 ASCO Annual Meeting

Combining Two Targeted Therapies Stalls Disease Progression in Melanoma Patients With BRAF Mutations

A combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has shown promising activity in patients with advanced melanoma.

Conferences   >   2012 ASCO Annual Meeting

Dr. Chapman on BRAF/MEK Combination for Melanoma

Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma

Conferences   >   2012 ASCO Annual Meeting

Metastatic Melanoma: Timely Approval of Yervoy

After a long fight with melanoma, the Roman Catholic parish priest Father Arthur Humphrey was able to receive the immunotherapeutic agent Yervoy, which greatly improved his prognosis.

OncLive Nursing   >   Patient Focus

Vemurafenib Study Builds on Positive Response Data

Vemurafenib continues to demonstrate clinical response and overall survival benefits for patients with metastatic melanoma.

Oncology Live   >   Clinical Insights

Krista Rubin on Managing Ipilimumab-related Dermatitis

Krista Rubin, MS, RN, FNP-BC, from Massachusetts General Hospital Cancer Center, on Managing Ipilimumab-related Dermatitis.

Conferences   >   2012 Oncology Nursing Society Congress

6-Fold Melanoma Increase Is Found Among Young Adults

Cutaneous melanoma is becoming increasingly common in young adults, with an 8-fold increase among young adult females and a 4-fold increase among young adult males.

Oncology Live   >   Clinical Insights

Special Report on Immunotherapy: Managing Yervoy's Side Effects

As an immunotherapy, Yervoy presents a unique set of side effects and it was approved along with a Risk Evaluation and Mitigation Strategy to address these events.

OncLive Nursing   >   Feature Story

Vemurafenib Doubles Median Survival in Metastatic Melanoma Patients

Vemurafenib nearly doubles the median OS in more than 50% of patients with BRAF V600-mutated metastatic melanoma.

  >   Web Exclusives

Targeted Therapies Yield Most Promising Results: A New Era in Melanoma Treatment Has Begun

Melanoma is one of the most frequent cancers; more than 2 million Americans are treated for skin cancer annually.

Oncology & Biotech News   >   Feature Article

Melanoma Breakthroughs Among Top 2011 Cancer Advances

Two novel treatments for advanced melanoma, ipilimumab (Yervoy) and vemurafenib (Zelboraf), were among the top breakthroughs in cancer research in 2011.

Oncology & Biotech News   >   News

Vismodegib, First Hedgehog Inhibitor, Approved for BCC Patients

The FDA has approved vismodegib for the treatment of patients with basal cell carcinoma.

  >   Web Exclusives

Researchers Discover Basis for Secondary Skin Cancers in Patients Taking Vemurafenib

The molecular basis behind the relatively high incidence of secondary skin cancers after patients received vemurafenib has been discovered.

  >   Web Exclusives

Study Supports Smaller Margins in Excising Thicker Melanomas

Patients with a primary cutaneous melanoma thicker than 2 mm can be safely treated with a 2-cm resection margin.

Oncology Live   >   Specialty Focus

NICE's Reluctance to Back Yervoy Turns on Cost-Benefit Perceptions

NICE has issued a draft recommendation against Yervoy approval, stating it does not show benefits to justify its costs.

Oncology Live   >   Specialty Focus

Chemoradiotherapy Shows Promise in Nonmelanoma Skin Cancer of the Head and Neck

Chemotherapy given at the same time as radiotherapy may be a feasible treatment for high-risk nonmelanoma skin cancer (NMSC) of the head and neck.

Oncology & Biotech News   >   Clinical Trial Reports

Hair Professionals Often Check Customers for Worrisome Skin Lesions

Some cosmetologists and barbers inspect their customers' scalps, necks, and faces for the presence of skin lesions that they think may be cancerous.

Oncology & Biotech News   >   Clinical Trial Reports

Novel Infusion Approach Significantly Delays Progression in Uveal Melanoma Patients With Liver Metastases

Patients with liver metastases from uveal melanoma had improved survival after treatment with percutaneous hepatic perfusion (PHP).

Conferences   >   The 2011 European Multidisciplinary Cancer Congress

ASCO 2011: What Nurses Need to Know

Personal perspectives from oncology nurses of abstracts presented at ASCO on research with the potential to change practice, important studies that failed to meet expectations, and topics particularly relevant to oncology nurses.

OncLive Nursing   >   Conference Highlights

ASCO Highlights: Trials in Progress

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

Oncology & Biotech News   >   Conference Highlights